Several clinical trials are ongoing, with encouraging results for sjögren’s syndrome (SS) and systemic sclerosis (SSc), reinforcing BAFF-targeting therapies as a potential strategy for autoimmune diseases treatment. The gene discussed is TNFSF13B; the disease is systemic sclerosis.